Scholarlink

Background <p>Multiple primary lung cancer is becoming increasingly common in clinical practice. It is divided into synchronous multiple primary lung cancer and nonsynchronous multiple primary lung cancer on the basis of a diagnostic interval of 6&#xa0;months. However, the diagnosis and treatment of multiple primary lung cancer face great challenges in clinical practice.</p> Case presentation <p>We report a case of a 66-year-old Chinese male patient with locally advanced synchronous multifocal lung cancer. In M 0&#xa0;months (the time of initial diagnosis), the patient underwent two cycles of carboplatin combined with albumin-bound paclitaxel induction chemotherapy before treatment was suspended due to personal reasons. In M + 10&#xa0;months, he resumed a personalized multimodal treatment regimen: induction chemotherapy combined with immunotherapy, concurrent chemoradiotherapy combined with targeted therapy, and adjuvant immunotherapy combined with targeted maintenance therapy. As of M + 72&#xa0;months, positron positron emission tomography–computed tomography showed lung metastasis, but his Karnofsky Performance Status score remained at 80, and he achieved progression-free survival of 72&#xa0;months. He continues to receive chemotherapy, tislelizumab immunotherapy, and recombinant human endothelin (Endostar) targeted therapy. As of M + 75&#xa0;months, he has survived for 75&#xa0;months without reaching the overall survival endpoint.</p> Conclusion <p>Clinical practice should adopt a multidisciplinary treatment-based approach, integrating clinical information, imaging data, histopathological features, and molecular characteristics to formulate individualized clinical management strategies and treatment plans. Such personalized therapeutic approaches are essential to improving long-term survival rates and quality of life in patients with synchronous multifocal lung cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of a personalized combination regimen combining induction chemotherapy, immunotherapy, radiotherapy, and targeted therapy for locally advanced synchronous multiple primary lung cancer: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月11日

查看全文
  • Yang Yao,
  • Zichao Xu,
  • Lijun Wang,
  • Mengqi Sun

摘要

Background

Multiple primary lung cancer is becoming increasingly common in clinical practice. It is divided into synchronous multiple primary lung cancer and nonsynchronous multiple primary lung cancer on the basis of a diagnostic interval of 6 months. However, the diagnosis and treatment of multiple primary lung cancer face great challenges in clinical practice.

Case presentation

We report a case of a 66-year-old Chinese male patient with locally advanced synchronous multifocal lung cancer. In M 0 months (the time of initial diagnosis), the patient underwent two cycles of carboplatin combined with albumin-bound paclitaxel induction chemotherapy before treatment was suspended due to personal reasons. In M + 10 months, he resumed a personalized multimodal treatment regimen: induction chemotherapy combined with immunotherapy, concurrent chemoradiotherapy combined with targeted therapy, and adjuvant immunotherapy combined with targeted maintenance therapy. As of M + 72 months, positron positron emission tomography–computed tomography showed lung metastasis, but his Karnofsky Performance Status score remained at 80, and he achieved progression-free survival of 72 months. He continues to receive chemotherapy, tislelizumab immunotherapy, and recombinant human endothelin (Endostar) targeted therapy. As of M + 75 months, he has survived for 75 months without reaching the overall survival endpoint.

Conclusion

Clinical practice should adopt a multidisciplinary treatment-based approach, integrating clinical information, imaging data, histopathological features, and molecular characteristics to formulate individualized clinical management strategies and treatment plans. Such personalized therapeutic approaches are essential to improving long-term survival rates and quality of life in patients with synchronous multifocal lung cancer.